11/25
07:00 am
bsem
BioStem Announces Notice of Allowance for U.S. Patent Application for Sterile Human Placental Allografts
Medium
Report
BioStem Announces Notice of Allowance for U.S. Patent Application for Sterile Human Placental Allografts
11/20
07:00 am
bsem
BioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare Global
Medium
Report
BioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare Global
11/12
07:29 am
bsem
BioStem Technologies Reports Record Third Quarter 2024 Revenue of $82.6 Million
Low
Report
BioStem Technologies Reports Record Third Quarter 2024 Revenue of $82.6 Million
10/29
07:00 am
bsem
BioStem Technologies Initiates Nationwide Launch of Vendaje AC® with Venture Medical Following Established Reimbursement in All Medicare Administrative Contractor (MAC) Regions
High
Report
BioStem Technologies Initiates Nationwide Launch of Vendaje AC® with Venture Medical Following Established Reimbursement in All Medicare Administrative Contractor (MAC) Regions
10/28
01:58 pm
bsem
BioStem Technologies to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
Low
Report
BioStem Technologies to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
10/17
07:00 am
bsem
BioStem Technologies Reports Breakthrough Results in a Diabetic Foot Ulcer Wound Closure Study Comparing BioREtain® to Standard of Care Treatment
Medium
Report
BioStem Technologies Reports Breakthrough Results in a Diabetic Foot Ulcer Wound Closure Study Comparing BioREtain® to Standard of Care Treatment
10/15
07:00 am
bsem
BioStem Technologies Establishes National Pricing for Vendaje AC® from the Center for Medicare Services and Provides Reimbursement in All MAC Regions
Medium
Report
BioStem Technologies Establishes National Pricing for Vendaje AC® from the Center for Medicare Services and Provides Reimbursement in All MAC Regions
10/2
07:00 am
bsem
BioStem Technologies Initiates BR-AC-DFU-101 Clinical Trial to Study BioREtain® in Diabetic Foot Ulcers
Medium
Report
BioStem Technologies Initiates BR-AC-DFU-101 Clinical Trial to Study BioREtain® in Diabetic Foot Ulcers
9/30
07:00 am
bsem
BioStem Technologies, Inc. Files Form 10 with the Securities and Exchange Commission and Submits Nasdaq Application for Uplisting
Low
Report
BioStem Technologies, Inc. Files Form 10 with the Securities and Exchange Commission and Submits Nasdaq Application for Uplisting